Novel strategies in the management of co-morbid chronic heart failure and kidney disease
- Prosjektnummer
- 2011062
- Ansvarlig person
- Dan Atar
- Institusjon
- Oslo universitetssykehus HF
- Prosjektkategori
- Postdoktorstipend
- Helsekategori
- Cardiovascular
- Forskningsaktivitet
- 5. Treatment Developement
Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis.
Int J Cardiol 2015;186():104-5. Epub 2015 mar 11
PMID: 25828104
Qualifying the use of common cardiovascular drugs in cardiology.
Circ J 2015;79(3):517-8. Epub 2015 feb 10
PMID: 25746532
Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
Circ Heart Fail 2015 Jan;8(1):71-8. Epub 2014 okt 31
PMID: 25362207
Digoxin withdrawal worsens clinical status in stable patients with heart failure receiving optimal contemporaneous therapy--a randomized controlled trial.
J Card Fail 2015 Sep;21(9):779-81. Epub 2015 jul 10
PMID: 26169443
Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative.
Eur J Heart Fail 2015 Nov;17(11):1144-51. Epub 2015 okt 1
PMID: 26424212
New medical therapies for heart failure.
Nat Rev Cardiol 2015 Dec;12(12):730-40. Epub 2015 sep 29
PMID: 26416006
Neprilysin inhibitors preserve renal function in heart failure.
Int J Cardiol 2015 Jan 20;179():329-30. Epub 2014 nov 6
PMID: 25464479
Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.
Circ Heart Fail 2013 May;6(3):594-605.
PMID: 23694773
Diuretic use in heart failure and outcomes.
Clin Pharmacol Ther 2013 Oct;94(4):490-8. Epub 2013 jul 12
PMID: 23852396
RAAS inhibitors and cardiovascular protection in large scale trials.
Cardiovasc Drugs Ther 2013 Apr;27(2):171-9.
PMID: 23224653
Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design.
Syst Rev 2013;2():7. Epub 2013 jan 18
PMID: 23327629
Current modalities for invasive and non-invasive monitoring of volume status in heart failure.
Heart 2012 Jul;98(13):967-73. Epub 2012 mai 9
PMID: 22572046
The Angiotensin-Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction
Circ Heart Fail. published online October 31, 2014;
Chapter 2. Pathophysiology and clinical manifestation of heart failure.
Advances in heart failure management. ISBN (print) 978-1-78084-147-2, Future Medicine Group 2012.
ARNi, combined neprilysin and angiotensin receptor inhibition augments anti-fibrotic and anti-hypertrophic effects in vitro.
European Heart Journal, 33:suppl. 1, 2012.
Molecular Mechanisms of Cardiac Hypertrophy and Heart Failure
LAP Lambert Academic Publishing AG & Co KG, 2011
Addition of neprolysin inhibitor to angiotensin receptor blocker provides superior anti-fibrotic and anti-hypertrophic effects
American College of Cardiology scientific sessions 2012
- Dan Atar Prosjektleder
- Henry Krum Medveileder
- Thomas Gero von Lueder Postdoktorstipendiat
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport